GLP1R and polycystic ovary syndrome: To effectively consider a patient with PCOS for GLP-1 analog therapy, screening for MS is essential as the primary indication and intended use should be to treat obesity (with a BMI >30) or a BMI >27, accompanied by concomitant metabolic dysfunctions such as HTN, dyslipidemia, obstructive sleep apnea (OSA), impaired fasting glucose, impaired glucose tolerance, and DM2 [68].